Why is FTT not yet able to build material value? Why are the...

Why is FTT not yet able to build material value?
Why are the investment speculators unwilling to make a bet?
Why is big-pharma ignoring this 'blockbuster'?

By now it is most likely well known - in an informal way through the usual investigative activities of big-pharma and professional speculators - which way the trial outcome is going to. Double-blinded or not, patients are people and people talk and others listen. And if this involves a potentially disruptive technology there are probably many big ears listening.

Could be some hidden strings tying FTT/TIS down we know nothing about.
As example, the xfer of IP from QUT(BlueBox) to TIS/FTT was announced and, I assume, did actually happen.
But, and that's a big but, has QUT actually given the stuff up without any strings (like caveats or prid-pro-quo's) attached to it?
It is my opinion that a commercial entity, like QUT(BlueBox), acting in such a benevolent way by voluntarily releasing (potentially a gold mine) IP and not asking for any return-in-kind is very rare indeed.
If there are any strings attached then the building of material value at this stage is not going to happen.
And it may even be a big hurdle for the future buildup too - even assuming a positive trial outcome.